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Background—NOD2 mutations and anti-Saccharomyces cerevisiae antibodies (ASCA) are
associated with Crohn’s disease (CD), ileal involvement and complicated disease behavior in
whites. ASCA and the three common NOD2 mutations have not been assessed in African
American (AA) adults with CD.
Methods—AA patients with CD and controls were recruited by the Mid-Atlantic African
American IBD Study (Johns Hopkins Hospital and satellite centers at Howard University,
University of Florida, University of North Carolina, University of Pennsylvania, and the
Washington Hospital Center, Washington, DC) as part of the NIDDK IBD Genetics Consortium.
Genotyping for the three common CD associated NOD2 mutations (Leu1007fsinsC, G908R/
2722g>c, and R702W/2104c>t) and ASCA ELISA assays were performed in 183 AA CD patients
and 143 controls. Positive ASCA was based on either IgA or IgG above threshold. CD
phenotyping was performed using the NIDDK IBD Genetics Consortium guidelines. Logistic
regression was used to calculate adjusted odds ratios (OR) for the association between ASCA and
disease phenotype.
Results—ASCA sensitivity and specificity in this AA population were 70.5% and 70.4%
respectively. On univariate analysis, ASCA was associated with younger mean age at diagnosis
(25.0±11.8 vs. 32.1±14.2 yrs, p<0.001), ileal involvement (73.0% vs. 48.0%, p=0.002), and
complicated (stricturing/ penetrating) behavior (60.3% vs. 41.7%, p=0.03). On multivariate
analysis, ASCA titer (/25U) was associated with ileal involvement (OR 1.18, 95% CI 1.04-1.34),
complicated behavior (OR 1.13, 95% CI 1.01-1.28) and surgery (hazard ratio 1.11, 95% CI
1.02-1.21). Risks for surgery also included smoking (hazard ratio 1.50, 95% CI 1.14-1.99) and CD
family history (hazard ratio 2.39, 95% CI 1.11-5.14). NOD2 carriers (all heterozygotes) were
more common among CD cases than controls (8.2 vs. 2.1%; OR 4.17, 95% CI: 1.18 - 14.69).
NOD2 mutation population attributable risk was 6.2%.
Conclusions—In comparison to whites, ASCA in AAs has a similar sensitivity but a lower
specificity for CD. ASCA is associated with ileal involvement, complicated behavior and surgery
in AAs with CD. NOD2 is a risk gene for AA CD, although mutation frequency and population
attributable risk are much lower than in whites.
INTRODUCTION
Crohn’s disease (CD) is a chronic, inflammatory bowel disease (IBD) that primarily
involves the ileum and/or colon. Underscoring the phenotypic heterogeneity of CD, previous
studies have identified CD phenotypes with distinct clinical features (age at diagnosis, site
of involvement, and family history), complications (inflammatory, stricturing and/or
penetrating behavior) and need for surgery (1-4).
Three NOD2 mutations (Leu1007fs/3020insC [Leu1007fsinsC], G908R/2722g>c, and
R702W/2104c>t), found commonly in all European ancestry populations (7 to 19% carriers
in controls vs. 16 – 45% in CD cases in hospital based studies) were the first identified and
remain the highest penetrance genetic risk factor for CD in white populations (5-7). NOD2-
associated overall risk was 2.4-fold for simple heterozygotes and 17-fold for homozygote/
compound heterozygote mutation carriers(7). NOD2 mutations have also been associated
with specific CD phenotypes: younger age at disease onset (8-11), ileal involvement (8, 9,
11-15), and complicated (stricturing and penetrating) behavior (8, 10-12, 16, 17).
Interestingly, expression of antibodies to Saccharomyces cerevisiae (ASCA) has been
associated with a CD phenotype that is remarkably similar to that of patients with NOD2
polymorphisms. ASCA seropositive patients present at a younger age (18-23) and are more
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likely to have ileal disease (18-25). They are also at greater risk for complicated disease
behavior (18, 21, 24-27) and require surgery more frequently (21, 24, 26, 28).
Our group reported a dose-response between the number of NOD2 mutations and the
prevalence and titers of ASCA (18), a finding that was also reported in studies from Italy
(11) and Hungary (29). Importantly, we also found that ASCA titer was associated with ileal
involvement and with complicated behavior, independently of NOD2 status (18).
To date, there have been no studies of ASCA in the African-American (AA) population. The
only study of NOD2 in AAs was in children and found that NOD2 alleles were infrequent in
AA children with CD in comparison to white children with CD (allele frequency 1.6% vs.
25.7%, p < 0.0001) (30). NOD2 mutations showed equal frequencies among 58 AA children
with CD relative to 124 controls (heterozygote carriers 3.8% vs. 4.3%, respectively).
However, the study was not adequately powered to assess NOD2 risk given the low
frequency of NOD2 mutations and low risk of heterozygotes, and controls were taken from
newborn screening dried blood spots. We and others have observed that AA patients with
CD have lower frequencies of an IBD family history (30-34) and ileal involvement (31, 35)
as compared to white CD patients. In view of the biologic and genetic heterogeneity of CD
and the differences in CD phenotype in AA patients, we performed a study to characterize
ASCA and the three common NOD2 mutations in CD in the AA population.
METHODS
Patient Population
The study population consisted of 334 individuals, self-identified as AA and recruited
between 2003-2007 by the Mid-Atlantic African-American Inflammatory Bowel Disease
Study (MAAAIS), a sub-study of the Inflammatory Bowel Disease Genetics Consortium
(IBDGC)(31). There were 190 unrelated patients with that carried a diagnosis of CD, and
144 matched, healthy controls. Blood for DNA purification and sera were successfully
collected from all study subjects. We included all study subjects available at this time.
MAAAIS is coordinated through the Meyerhoff IBD Center at Johns Hopkins University
with recruitment from the Meyerhoff IBD Center clinics, the Johns Hopkins Hospital and
from satellite recruitment at the IBD centers at Howard University, University of Florida,
University of North Carolina, University of Pennsylvania, and the Washington Hospital
Center, Washington, DC. Subjects were also referred to the Johns Hopkins coordinating site
by their gastroenterologists in the state of Maryland or by the Maryland, Washington and
Northern Virginia Chapter of the Crohn’s and Colitis Foundation of America (CCFA), or
were self-referred after learning about the study from IRB-approved advertisements for AA
patients and AA healthy controls in Baltimore area newspapers. Healthy controls were the
non-genetically related spouse, partner or friend of the case, and were without a known
personal or family history of IBD. The controls were recruited by each center primarily by
referral from cases. When cases were unable to refer a control, population controls living in
the same geographic region (i.e. identical first 3 digits of mail “zip” code) and matched by
age and sex were also recruited. An additional 26 CD cases and 13 controls were also
included that were unrelated AA participants of the Meyerhoff IBD Center genetics research
studies between 1997 and 2003 and that had both sera and DNA.
AA ethnicity was self-defined. In addition, as part of a separate study, we had genotyped 96
African/European admixture informative markers with comparison to West African and
European controls, and average ethnicity was identical between cases and controls (78.9%
vs. 80.2% average West African ancestry, respectively)(36). One of the controls had 98%
European ancestry and was excluded. None of the remaining participants had less than 28%
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West African ancestry. Diagnosis of CD was confirmed by chart review, in accordance with
the NIDDK IBDGC requirements (31).
DNA samples were successfully isolated in 100% of study subjects. DNA was purified from
blood by use of a Gentra Puregene kit (Qiagen, Valencia, CA). Samples from cases and
controls were plated for genotyping or serotyping together, and laboratory personnel were
blinded as to disease status. In each genotyping plate, water controls were used to control for
cross sample contamination and samples of known genotypes and duplicate samples (placed
in wells on two different plates), were placed as negative and positive controls.
Phenotyping
CD phenotyping was performed using a previously validated protocol and in accordance
with the Montreal classification(37, 38). Age at diagnosis was determined by chart review
and if necessary by patient questionnaire. For disease location, patients were classified into
one of four mutually exclusive groups: 1) L1: ileum involvement only; 2) L2: colonic
involvement only; 3) L3: ileocolonic involvement; and 4) L4: isolated upper gastrointestinal
involvement. Disease location was determined as maximal extent of the disease. As
specified in the Montreal classification, perianal and rectovaginal fistulae did not, by
themselves, constitute penetrating disease. History of surgery was confirmed bowel
resection or diversion for treatment of CD or complications. History of immunomodulator
use was defined as any history, captured in the medical records or reported by the patient, of
azathioprine, 6-mercaptopurine or methotrexate use. History of infliximab use was
infliximab therapy as reported in the medical records or by the patient. Family history of CD
was defined as CD in a 1st or 2nd degree relative (e.g., parent, sibling, grandparent, or
avuncular relative). Current smoking was defined as consumption of a minimum of 7
cigarettes per week for at least 1 year.
NOD2 Genotyping
Patients were genotyped for Leu1007fsinsC and G908R/2722g>c polymorphisms using the
TaqMan method as described (39). R702W/2104c>t status was determined by PCR
amplification of NOD2 exon 4, column purification and direct sequencing.
ASCA
Sera were analyzed for the presence of S. cerevisiae IgG and IgA antibodies by a
commercially available enzyme-linked immunosorbent assay (ELISA) according to the
manufacturer’s specifications (QUANTA Lite, INOVA Diagnostics, San Diego, CA). The
test result is calculated by multiplying the ratio of sample to control optical density (OD)
with the number of units assigned to the control by the manufacturer. Reactivity is related to
the quantity of antibody present in a nonlinear fashion. Results are classified as negative (0.0
–20.0 Units, U), equivocal (20.1–24.9 U), and positive (≥25 U). Our ASCA assay correlates
well with the assay of Prometheus Laboratories (San Diego, CA), which is the most
commonly used assay in the United States (40).
Statistical analysis
Statistical analysis was performed with the Stata 10 (College Station, Texas, USA). Patients
were considered ASCA+ if they were ASCA IgA-positive (ASCA IgA+) and/or ASCA IgG-
positive (ASCA IgG+). Since stricturing and penetrating behaviors represent more
complicated disease that almost always necessitates surgery, we analyzed jointly these
patients, as we also did in our prior study of white CD patients (18).
Patient genotypes were divided into three groups: “MM,” patients carrying two NOD2
mutant alleles (homozygotes or compound heterozygotes); “MW,” those carrying a single
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NOD2 mutant allele and a single wild type allele; and “WW,” those carrying only wild type
alleles.
The prevalences of ASCA in the CD and control populations were compared using the chi-
square statistic. Characteristics of ASCA+ and ASCA− patients were compared using the
Wilcoxon ranksum test for continuous variables, and the chi-square or Fisher’s exact test for
nominal categorical variables. The prevalences of NOD2 mutations and NOD2 allele
frequencies in CD cases and controls were compared using the Fisher exact test. Population
attributable risk (PAR) in AA was calculated as per Schlesselman (41): PAR =
[Pe*(OR-1)] / [ Pe*(OR-1) + 1], where Pe is the prevalence of exposure (NOD2 mutation)
in the population, and OR is the odds ratio for CD and any NOD2 mutation..
The independent association of ASCA titer and other factors with the presence of ileal
involvement and stricturing/penetrating behavior was evaluated with logistic regression
adjusting for disease duration, age at diagnosis, family history, and smoking at time of
diagnosis. We used Cox proportional hazards to assess the association between ASCA titer
and time to surgery while adjusting for the same covariates used for the logistic regression
models. Disease behavior was not included in the model for disease site, since disease
behavior evolves over time. Disease behavior was also not included in the model for time to
surgery, since disease behavior is frequently determined near or at the time of surgery.
Ethical Considerations
The Institutional Review Boards of the Johns Hopkins Medical Institutions, the University
of North Carolina, the University of Pennsylvania, Washington Hospital Center, the
University of Florida and Howard University approved the study and informed consent was
obtained from all patients.
RESULTS
Patient characteristics
Among the 190 unrelated AA patients recruited who carried a diagnosis of CD based on
their physicians’ assessment, our review of primary medical records confirmed a diagnosis
of CD in 183 cases (with 1 case reclassified as indeterminate colitis). After exclusion of one
control who had less than 15% West African ancestry, there were 143 controls. The
characteristics of these studied CD cases and controls are presented in Table 1. Mean (SD)
age of patients at diagnosis was 27.1 (12.9) years. A family history of IBD was observed in
11.5% of patients. Ileal involvement (isolated ileal or ileocolonic) was seen in 66.0%.
Disease behavior was inflammatory in 45.0%, stricturing in 30.8%, and penetrating in
24.2%. Immunomodulators and infliximab were used in 62.8% and 42.8% of patients
respectively.
ASCA
Among the 183 AA patients with CD, 129 (70.5%) were ASCA+. ASCA data were available
for 142 controls. Among the controls, 100 were ASCA−, yielding an ASCA specificity for
CD of 70.4%. Age at diagnosis was significantly lower in ASCA+ patients (25.0±11.8 vs.
32.1±14.2, p<0.001) (Table 2). On univariate analysis, ASCA+ status was also associated
with ileal involvement (73.0% vs. 48.0%, p=0.002), complicated (stricturing or penetrating)
behavior (60.3% vs. 41.7%, p=0.03), and surgery (63.0% vs. 47.2% p =0.05). ASCA+ and
ASCA− patients did not differ in terms of gender, family history of IBD, tobacco use, and
immunomodulator and infliximab therapy.
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NOD2 data were available for all cases and controls. All individuals carrying NOD2
mutations were simple heterozygotes and carriage of any NOD2 mutation was 8.2%
(15/183) among patients, compared to 2.1% (3/143) in controls (p=0.03) (Table 1). The OR
for CD and any NOD2 SNP was 4.17 (95% confidence interval (CI): 1.18 - 14.69) with a
population attributable risk of 6.2%. Of the three alleles investigated, only Leu1007fsinsC
was significantly more frequent in patients than controls (0.019 vs. 0.000; p=0.02) (Table 1).
The MW genotype was seen among 7.0% and 11.1% of ASCA+ and ASCA− cases,
respectively (Table 2).
We found no association between any NOD2 mutation and ileal involvement or CD
behavior. In addition, no association was seen between individual mutations and any
phenotypic characteristics (data not shown). However, with so few NOD2 cases, we had
limited power to identify very strong effects.
Multivariate analysis
We evaluated the independent association of ASCA titer as a continuous variable, to ileal
(L1 or L3) involvement using multiple logistic regression (Table 3). Ileal involvement was
independently associated with ASCA titer (OR 1.18 per 25 unit increase, 95% CI 1.04–1.34,
p=0.01) after adjustment for age at diagnosis, disease duration, family history, and smoking.
Stricturing and penetrating behaviors are encountered more frequently in patients with ileal
disease. We therefore investigated whether the association between ASCA and complicated
behavior persisted after accounting for the contribution of ileal involvement. On multiple
logistic regression (Table 4), ASCA titer was associated with complicated behavior (OR
1.13 per 25 unit increase, 95% CI 1.01 – 1.27). Additionally, complicated disease behavior
was independently associated with ileal involvement (OR: 3.97, 95% CI: 1.84 – 8.54) and
longer disease duration (OR: 1.75 per 10 years, 95% CI: 1.11–2.75).
Table 5 gives the results of the analysis of time to surgery. Shorter time to surgery was
associated with ASCA titer (hazard ratio (HR) 1.11 per 25 unit increase, 95% CI 1.02 –
1.22), family history of CD (HR: 2.39, 95% CI: 1.11–5.14) and smoking (HR 1.50; 95% CI
1.14-1.99).
DISCUSSION
Our study is the first to assess ASCA and the three common NOD2 mutations in AA adults
with CD. We report the following findings: 1) The sensitivity of ASCA for CD in AAs was
70.5%; 2) The specificity of ASCA for CD was 70.4%; 3) ASCA was independently
associated with earlier disease onset, ileal involvement, complicated behavior, and surgery;
4) Although less common than in whites, the presence of a NOD2 mutation, and specifically
Leu1007fsinsC, was for the first time shown to be a risk factor for CD in African
Americans.
In a previous study (31), we found that AA adult patients with CD were significantly more
likely than whites to develop upper GI disease (OR, 2.8), colorectal involvement (OR, 1.9),
perianal disease (OR, 1.7), and particularly extra-intestinal manifestions of uveitis and
sacroileitis (OR 5.5 and 4.0, respectively). Conversely, AA patients were less likely to have
ileal involvement (OR, 0.55) or internal penetrating disease (OR, 0.59). A family history of
IBD was present less frequently in AA than their white counterparts (20 vs. 31%, p<0.05).
Other studies have also found differences in CD family history and phenotypic
manifestations by race (30, 32-35). Differences between white and AA CD patients in
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family history, disease location, and extraintestinal manifestations suggest potential genetic
and environmental differences.
Numerous studies have linked CD phenotypes with genetic polymorphisms. NOD2
mutations have been associated with ileal involvement and complicated behavior (8-10,
12-17). Although NOD2 is a confirmed CD susceptibility gene in white populations, NOD2
mutations are rare or absent among other ethnic groups (42-44). To date, only one study in a
population from Wisconsin, USA, has assessed NOD2 mutations in the AA population (30).
In that report, NOD2 allele frequencies were markedly lower in AA vs. white children, both
among healthy controls (2.1 vs. 9.1%, p<0.01) and among CD patients (1.6% vs. 25.7%,
p<0.0001). There was no observed association between NOD2 and CD in the AA children.
Yet, given the small size (58 cases and 124 controls) and the low NOD2 mutation frequency
in the AA population, the study was underpowered to observe the overall 3-fold risk seen for
NOD2 mutation carriers seen in European ancestry studies (7). For example, a meta-analysis
of 29 non-Jewish, white, hospital-based studies reported a NOD2 risk of 3.2 (95% CI: 2.8 –
3.6) for all NOD2 carriers, with OR 2.4 (95% CI 2.0 – 2.9) for simple heterozygotes (MW)
and 17.1 (95% CI 10.7 – 27.2) for two mutant allele carriers (MM) (7). NOD2 risk in our
study (OR for heterozygotes 4.17, 95% CI: 1.18 - 14.69) was therefore within the same
range. Nonetheless, the lower frequency of NOD2 in the AA population relative to white
populations results in a much smaller population attributable risk, only 6.2% in AA vs. 22%
in non-Jewish whites (7).
We did not observe any NOD2 mutant homozygotes or compound heterozygotes and given
the low NOD2 mutation allele frequency in both ours and the Wisconsin AA controls,
(assuming Hardy-Weinberg equilibrium) only 0.01 to 0.04% of AA individuals would be
expected to be NOD2 homozygotes, as compared to the 0.5% of whites observed in a large
study (45). It should be noted that the three NOD2 mutations are assumed to arise only from
European admixture. R702W and G908R mutations were not present in 118 chromosomes
genotyped in the Yoruban population (HapMap YRI database). Gasche et al. recently
genotyped the three NOD2 mutations in DNA from 7 sub-Saharan African populations
(including 25 Yorubans) and did not identify any NOD2 mutations, including
Leu1007fsinsC. (46). In a study of 3,575 healthy whites from around the world, NOD2
allele frequency was 7.8% (45). European-African admixture among AA population has
been considered as a continual process over four centuries, and the presence of NOD2
mutations may be affected by survival advantages and disadvantages. For example, NOD2
mutations may produce a survival advantage to exposure to certain infectious pathogens (46,
47). The 1.1% allele frequency we observed among AA controls is lower but within error of
that expected from the 20% overall white admixture in AAs. It will be important to perform
larger studies of NOD2 in AA CD cases and healthy controls to 1) better define the overall
AA population risk of NOD2; 2) assess whether NOD2 in the AA population is below that
expected by overall white admixture; and 3) determine whether the low rate of NOD2
indeed explains the lower frequency of ileal CD in AAs.
With regard to individual mutations, only the Leu1007fsinsC was significantly associated
with CD. The frequency of the Cins allele was 1.9% in patients vs. 0% in controls (p=0.02).
In a meta-analysis of European ancestry studies, Economou and colleagues also observed
that carriers of the Cins allele had a risk (OR 4.1; 95% CI 3.2 – 5.2) significantly greater
than carriers of the R702W allele (OR 2.2; 95% CI 1.8 – 2.6), and a trend towards a greater
risk than carriers of the G908R allele (OR 3.0; 95% CI 2.4 – 3.7) (7). As in nearly all NOD2
studies, we observed that the G908R and R702W allele frequencies were numerically
greater in CD vs. controls (R702W: 1.6% vs. 1.1%; G908R: 0.5% vs. 0.0%), but the
differences did not reach statistical significance. Note that we had only 30% power to
observe a significant association for the presence of any NOD2 mutation, given the overall
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mutant allele frequency of 0.010 in AA controls, and assuming the meta-analysis NOD2
risks observed in whites. Therefore, much larger studies will be needed to assess the risk of
the individual alleles. NOD2 mutations were not a risk factor for ileal disease or complicated
disease in the AA population, but again the study was underpowered.
ASCA expression has been associated in white populations with ileal involvement, earlier
age at onset, stricturing and penetrating CD, and need for surgery (18-28). Furthermore, we
found that the ASCA titer was associated with complicated behavior independent of
NOD2status and ileal involvement. However, it is not known whether ASCA retains its
phenotypic associations in AAs with CD, a population with a lower frequency of NOD2
mutations and, probably, a different disease phenotype. Using the cutoff values determined
by the manufacturer, the sensitivity and specificity values of our ASCA assay (QUANTA
Lite, INOVA Diagnostics, San Diego, CA) in the AA CD population were 70.5% and 70.4%
respectively. In comparison, the sensitivity of the QUANTA Lite assay in whites has ranged
between 48%-76% (18, 22, 48, 49). Assay specificity was somewhat lower than the values
observed in whites (86%-89%) (40, 48, 49). These differences should be placed in
perspective by recognizing that the diagnostic accuracy of a test depends on the spectrum of
diseased and non-diseased individuals comprising the study populations. As in whites,
ASCA was associated with earlier disease onset, ileal involvement, complicated behavior
and surgery in AA patients as well. On multivariate analysis, ASCA titer remained
associated with ileal involvement, complicated behavior, and surgery. In this study, ASCA
was not associated with NOD2 mutations in AA, but there was a small number of NOD2
carriers. ASCA seroprevalence is similar in whites and AAs, whereas NOD2 mutations are
much less common in AAs compared to whites. Therefore, other genes may be associated
with the generation of ASCA in AAs .
In summary, ASCA in AAs was associated with CD diagnosis, earlier disease onset, ileal
involvement, complicated behavior, and surgery. In the AA population, the Leu1007fsinsC
NOD2 mutation was associated with CD diagnosis. However, NOD2 mutations, the
strongest genetic risk factors identified for CD, account for a much smaller proportion of CD
among the AA population than among white populations. Nonetheless, the incidence of CD
in both populations in the United States has been found to be similar (50). Therefore further
studies are needed to assess the importance of other CD risk genes in AA and to identify
specific novel genetic and potential environmental risk factors in this understudied
American population.
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1. WHAT IS CURRENT KNOWLEDGE
• Common NOD2 mutations (R702W, G908R and Leu1007fsinsC) are
genetic risk factors for Crohn’s disease in whites.
• The presence of anti-Saccharomyces cerevisiae antibodies (ASCA) is
associated with Crohn’s disease in whites.
• Both NOD2 mutations and ASCA are established risks for ileal
involvement and complications of intestinal stricturing and internal
fistulas in whites.
• NOD2 is rare in African Americans (AA).
2. WHAT IS NEW HERE
• NOD2 is a genetic risk factor for Crohn’s disease in AAs with a similar
risk for heterozygotes as that observed for whites, although the
frequency of NOD2 mutations and the population attributable risk are
significantly lower than those observed in whites.
• NOD2 mutation homozygotes and compound heterozygotes were not
observed in either Crohn’s disease cases or controls and are thus likely
to be very uncommon.
• Among the three NOD2 mutations, there was evidence of a significant
Crohn’s disease association for the Leu1007fsinsC mutation in AAs.
• ASCA sensitivity in AAs was 70.5%, similar to values observed in
white. ASCA specificity was 70.4%, somewhat lower than values in
whites.
• Similar to white populations, ASCA in AAs is a risk for younger onset
Crohn’s disease, ileal involvement,complicated (stricturing/internal
penetrating) behavior, and surgery.
• In AA with CD, elevated ASCA titers, smoking and CD family history
are independent risk factors for surgery.
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TABLE 1
Demographic and phenotypic characteristics, ASCA serotypes and NOD2 genotypes among cases and
controls
Cases (n=183) Controls (n=143) p-value
Age at diagnosis (SD)
(n = 182 for cases)
27.1 (12.9) N/A
Age at study entry (SD) 38.2 (14.0) 39.6 (11.8) 0.17
Female 121 (66.1%) 88 (61.5%) 0.39
Family history of IBD 21 (11.5%) 0.0 <0.001
Smoking (at study entry)
(171 cases, 141 controls)
0.04
 Never 96 (56.1%) 70 (49.7%)
 Former smoker 35 (20.5%) 20 (14.2%)
 Current 40 (23.4%) 51 (36.2%)
Smoking (at diagnosis)
(171 cases)
 Never 111 (65.3%) N/A
 Former 14 (8.2%) N/A
 Yes 45 (26.5%) N/A
ASCA+
(142 controls)
129 (70.5%) 42 (29.6%) <0.001
Any NOD2 mutation 15 (8.2%) 3 (2.1%) 0.03
 G908R 2 (1.1%) 0 0.51
 Leu1007fsinsC 7 (3.8%) 0 0.02
 R720W 6 (3.3%) 3 (2.1%) 0.74
NOD2 allele frequency 0.040 0.010 0.03
 G908R 0.005 0 0.51
 Leu1007fsinsC 0.019 0 0.02
 R720W 0.016 0.010 0.74
NOD2 genotype 0.03
  WW 168 (91.8%) 140 (97.9%)
  MW 15 (8.2%) 3 (2.1%)
  MM 0 0
Disease location (n=174)a N/A
 L1: Ileal 35 (20.1%)
 L2: Colonic 57 (32.8%)
 L3: Ileocolonic 80 (46.0%)
 L4: Isolated upper GI 2 (1.1%)
Any ileal involvement (n=177)b 117 (66.1%) N/A
Behavior (n=169) N/A
 Inflammatory 76 (45.0%)
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Cases (n=183) Controls (n=143) p-value
 Stricturing 52 (30.8%)
 Penetrating 41 (24.2%)
Any complicated (n=169) 93 (55.0%) N/A
Any perianal disease (n=172) 60 (34.0%) N/A
Immunomodulator use 115 (62.8%) N/A
Infliximab use (n=180) 77 (42.8%) N/A
Surgery (n=180) 105 (58.3%) N/A
a
Included persons with complete information to determine both ileal and colonic involvement
b
Included persons with complete information to determine ileal involvement
Abbreviations: SD, standard deviation IBD, inflammatory bowel disease ASCA, antibodies to Saccharomyces cerevisiae NS, not significant N/A,
not applicable















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Dassopoulos et al. Page 17
Table 3
Adjusted Odds Ratios for any Ileal (isolated ileal or ileocolonic) Disease Versus Isolated Colonic Disease
OR 95% CI p-value
ASCA (/25 U) 1.18 1.04-1.34 0.012
Age at diagnosis (/10 years) 0.79 0.60-1.04 0.09
Family history of CD 1.90 0.58-6.19 0.29
Smoking 0.95 0.59-1.53 0.84
Disease duration (/10 years) 1.00 0.66-1.49 0.98
Abbreviations: OR, odds ratio CI, confidence interval ASCA, antibodies to Saccharomyces cerevisiae CD, Crohn’s disease
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TABLE 4
Adjusted Odds Ratios for Complicated CD Behavior
OR 95% CI p-value
ASCA (/25 U) 1.13 1.01-1.27 0.04
Age at diagnosis (/10 yrs) 1.08 0.81-1.43 0.62
Family history of CD 0.63 0.22-1.77 0.38
Smoking 1.14 0.70-1.87 0.59
Ileal involvement 3.97 1.84-8.54 <0.001
Disease duration (/10 yrs) 1.75 1.11-2.75 0.02
Abbreviations: OR, odds ratio CI, confidence interval ASCA, antibodies to Saccharomyces cerevisiae CD, Crohn’s disease
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Table 5
Hazard Ratios for Having Surgery
HR 95% CI p
ASCA (/25 U) 1.11 1.02-1.22 0.02
Age at diagnosis (10 yrs) 0.96 0.75-1.23 0.76
Family history of CD 2.39 1.11-5.14 0.03
Smoking 1.50 1.14-1.99 0.004
Ileal involvement 1.40 0.75-2.62 0.30
Disease duration (/10 yrs) 1.11 0.78-1.57 0.57
Abbreviations: HR, hazard ratio CI, confidence interval ASCA, antibodies to Saccharomyces cerevisiae CD, Crohn’s disease
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